MedTrace Logo

Study of CM326 Injection in Healthy Subjects

NCT05715333 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 46

Last updated 2024-11-08

No results posted yet for this study

Summary

This study is a single-center, randomized, double-blind, placebo-controlled, dose-increasing phase I clinical study.

Conditions

  • Healthy

Interventions

BIOLOGICAL

CM326

CM326 Injection

OTHER

Placebo

Subcutaneous injection

Sponsors & Collaborators

  • Keymed Biosciences Co.Ltd

    lead INDUSTRY

Principal Investigators

  • Jie Hou · Peking University Care Luzhong Hospital

  • Hong Wang · Peking University Care Luzhong Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-03-21
Primary Completion
2023-10-04
Completion
2023-10-04

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05715333 on ClinicalTrials.gov